ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 145 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $48,393,442 | +38.9% | 7,064,736 | +110.2% | 1.30% | +34.4% |
Q2 2023 | $34,852,958 | +28.2% | 3,360,941 | 0.0% | 0.97% | -2.3% |
Q1 2023 | $27,190,013 | -47.3% | 3,360,941 | +2.6% | 0.99% | -54.4% |
Q4 2022 | $51,605,552 | -17.6% | 3,276,543 | -17.6% | 2.18% | -15.8% |
Q3 2022 | $62,591,000 | +12.8% | 3,976,543 | 0.0% | 2.59% | -3.5% |
Q2 2022 | $55,513,000 | -19.0% | 3,976,543 | 0.0% | 2.68% | -2.2% |
Q1 2022 | $68,556,000 | +178.0% | 3,976,543 | +134.5% | 2.74% | +206.4% |
Q4 2021 | $24,658,000 | -0.2% | 1,695,904 | +23.5% | 0.90% | -7.2% |
Q3 2021 | $24,715,000 | +40.7% | 1,373,044 | +37.3% | 0.96% | +46.5% |
Q2 2021 | $17,560,000 | – | 1,000,000 | – | 0.66% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |